Psychedelics: An Emerging Frontier for Brain Injury Treatment
Psychedelics such as psilocybin, LSD and DMT are being studied for brain injury because, in cell cultures and animals, they lower inflammatory signaling and encourage neurons to form new connections. As of September 2026, no completed human trial has tested any of them in people with a traumatic brain injury or stroke. The first randomized trial for persistent concussion symptoms opened at Monash University in June 2026.
Key takeaways
- The 2021 Frontiers in Neurology paper this article covers is a narrative review of cell, animal and case-report data. Its authors call for phase II trials before drawing conclusions.
- In rats, DMT shrank stroke lesions and psilocybin restored behavior a full year after injury. Neither result has been reproduced in people.
- The psilocybin trials that showed antidepressant effects enrolled people with depression, not people with brain injuries.
- Psilocybin, LSD and DMT are Schedule I under United States federal law. This page summarizes research. It does not recommend use.
This article is educational and is not medical advice. It does not recommend starting, stopping or changing any treatment. The substances discussed are illegal to possess outside approved clinical trials and a small number of state-regulated programs. If you are recovering from a brain injury, your neurologist or rehabilitation physician is the right person to discuss any of this with.
What the 2021 review said
Evidence: narrative review, secondary source
Khan, Carter, Aggarwal and Holland published Psychedelics for Brain Injury: A Mini-Review in Frontiers in Neurology on July 29, 2021.1 They searched PubMed for work on the neuroprotective side of psychedelics rather than the psychotherapy side, and grouped what they found under four headings: neuroinflammation, neuroplasticity, hippocampal neurogenesis and brain complexity. The paper also cites cannabinoid and ketamine findings in places, so not every result in it comes from a classic psychedelic.
Their conclusion was more restrained than the way this article first described it. The authors wrote that the historical safety record of some of these compounds could stand in for early-phase safety data, and that phase II trials would be needed to learn whether any of them help with TBI or with reperfusion injury after stroke.1 A narrative review is a summary written by its authors, not a systematic search with predefined inclusion rules, which is why I rate it as a secondary source.
A publisher erratum on September 30, 2021 added a junior reviewer, Paolo Cardone of the University of Liège, who had been left off the peer-review credits.2 The correction changed nothing in the paper itself.
How psychedelics act on injured brain tissue
Evidence: cell culture and animal studies
Three mechanisms come up repeatedly in the laboratory work, and each has been measured in cells or rodents rather than in people.
Inflammatory signaling
After an injury the brain releases cytokines such as TNF-alpha, IL-1 beta and IL-6. In the rat stroke study described below, DMT lowered all three and raised the anti-inflammatory cytokine IL-10.3 Part of this activity runs through the sigma-1 receptor rather than the serotonin 2A receptor that produces the psychedelic experience, since blocking sigma-1 removed most of the benefit.3
Structural plasticity
Ly and colleagues at UC Davis reported in 2018 that LSD, DMT and DOI increase dendritic branching, spine density and synapse formation in cultured cortical neurons, with matching structural changes in rats and fruit flies.4 The effect depended on BDNF signaling through the TrkB receptor and on the mTOR pathway. The authors framed the work around depression, and every measurement was taken in cells or animals.4
Serotonin 2A receptor recovery
Rats imaged a full year after a fluid-percussion brain injury showed lower 5-HT2A receptor binding on PET scans, along with microglia in the prefrontal cortex that had fewer branches and enlarged cell bodies. A single dose of psilocybin restored the receptor binding and reduced microglial density over the following two weeks.5
Stroke and TBI: the animal evidence
Evidence: rodent studies, no human replication
Stroke
Nardai's group at Semmelweis University in Budapest blocked the middle cerebral artery in rats for 60 minutes and began a continuous DMT infusion before reperfusion. MRI at 24 hours showed a lesion volume of 135 cubic millimeters in treated animals against 205 in controls, and the treated rats recovered motor function faster.3 Each group held ten rats, which is a typical size for this kind of work and far too small to say anything about people.
Chronic TBI
The Monash University study from June 2026 is the most relevant TBI dataset so far because dosing came one year after the injury, which is closer to how a person with lasting symptoms would present than dosing on the day of a head impact.5 Sensorimotor and memory performance improved within days of a single dose, and so did measures of mood-related behavior. The same group has now moved to a human trial, covered below.
Repeated mild head injury
A Northeastern University team posted a preprint in February 2025 reporting that psilocybin given after each of three daily head impacts in female rats reduced brain swelling, restored functional connectivity on MRI, lowered phosphorylated tau and raised BDNF and its receptor TrkB.6 A preprint has not passed peer review. I have included it because the design is close to sport-related concussion, and I will update this section when a journal version appears.
What has been tested in people
Evidence: no completed trials in brain injury populations
No completed randomized trial has given a psychedelic to people with a TBI or stroke. The two psilocybin trials most often cited in this context enrolled people with major depression: a Johns Hopkins trial of psilocybin-assisted therapy published in 2021, and an Imperial College London comparison against the antidepressant escitalopram the same year.78 Both reported antidepressant effects. Neither included anyone with a brain injury, so they say nothing about how injured tissue responds or whether the same dose is safe after a concussion.
The trial announced by Monash University on June 15, 2026 is the first randomized, double-blind, active-placebo study of psilocybin-assisted therapy for post-concussion symptoms that have lasted six months or longer.9 It grew directly out of the rat study above. Results are years away, and until they arrive the human evidence consists of case reports and surveys, which cannot separate the drug from expectation, setting or the passage of time.
For the herbs and therapies that do have some human data behind them after a head injury, see my article on herbal and complementary support for TBI recovery.
Risks and legal status
Evidence: pharmacology and the regulatory record
Psilocybin, LSD and DMT are Schedule I substances under United States federal law. Oregon and Colorado license supervised psilocybin sessions under state law, and possession outside those programs remains a crime in most of the country. Clinical trials operate under a separate federal exemption.
The research itself points to specific cautions for anyone with a brain injury. Seizures are more common after TBI, and serotonin 2A agonists have not been studied in people with a post-injury seizure history. The same receptor family raises heart rate and blood pressure during a session. SSRIs, MAOIs, lithium and tramadol all interact with these compounds. A personal or family history of psychosis is an exclusion criterion in every trial I have read. Microdosing has survey data and no controlled study after a brain injury, so there is no dose, schedule or product I can point to as tested.
Frequently asked questions
Evidence: summary of the sources above
Can psilocybin repair a brain injury?
Not in any human study. In rats, a single dose one year after injury restored serotonin receptor binding and improved behavior.5 Whether that translates to people is the question the Monash trial was built to answer.
Is there a clinical trial of psychedelics for concussion?
Yes. Monash University in Melbourne opened a randomized, double-blind trial of psilocybin-assisted therapy for persistent post-concussion symptoms in June 2026.9 No results have been published.
Which psychedelic has the most brain injury evidence?
Psilocybin, on the strength of two rodent TBI studies published in 2025 and 2026.56 DMT has the only animal stroke data.3 LSD has cell-culture plasticity data and nothing in an injury model.4
Sources
- Khan M, Carter GT, Aggarwal SK, Holland J. Psychedelics for Brain Injury: A Mini-Review. Front Neurol. 2021;12:685085. doi:10.3389/fneur.2021.685085 (narrative review, secondary source)
- Frontiers Production Office. Erratum: Psychedelics for Brain Injury: A Mini-Review. Front Neurol. 2021;12:772692. doi:10.3389/fneur.2021.772692
- Nardai S, László M, Szabó A, et al. N,N-dimethyltryptamine reduces infarct size and improves functional recovery following transient focal brain ischemia in rats. Exp Neurol. 2020;327:113245. PMID 32067950. (rat study)
- Ly C, Greb AC, Cameron LP, et al. Psychedelics Promote Structural and Functional Neural Plasticity. Cell Rep. 2018;23(11):3170-3182. doi:10.1016/j.celrep.2018.05.022 (cell culture, rat and fly study)
- Allen J, Jupp B, Baker TL, et al. Psilocybin restores behavior and 5-HT2A signaling while reducing microglial density after chronic traumatic brain injury in rats. Cell Rep Med. 2026;7(7):102867. doi:10.1016/j.xcrm.2026.102867 (rat study)
- Brengel EK, et al. Psilocybin as a Treatment for Repetitive Mild Head Injury: Evidence from Neuroradiology and Molecular Biology. bioRxiv. February 2025. doi:10.1101/2025.02.03.636248 (preprint, not peer reviewed, lower confidence)
- Davis AK, Barrett FS, May DG, et al. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2021;78(5):481-489. doi:10.1001/jamapsychiatry.2020.3285 (depression population, not brain injury)
- Carhart-Harris R, Giribaldi B, Watts R, et al. Trial of Psilocybin versus Escitalopram for Depression. N Engl J Med. 2021;384(15):1402-1411. doi:10.1056/NEJMoa2032994 (depression population, not brain injury)
- Monash University. Monash researchers launch new clinical trial testing psychedelic therapy for post-concussion symptoms. June 15, 2026. monash.edu (institutional announcement, no results)
